China National Accord Medicines Corporation Ltd. (SHE:000028)
24.53
+0.01 (0.04%)
May 8, 2026, 3:04 PM CST
SHE:000028 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 72,308 | 72,778 | 73,675 | 74,844 | 72,701 | 67,648 |
Other Revenue | 637.52 | 637.52 | 703 | 633.35 | 742.57 | 710.01 |
| 72,946 | 73,416 | 74,378 | 75,477 | 73,443 | 68,358 | |
Revenue Growth (YoY) | -0.86% | -1.29% | -1.46% | 2.77% | 7.44% | 14.60% |
Cost of Revenue | 65,266 | 65,618 | 66,180 | 66,471 | 64,561 | 60,372 |
Gross Profit | 7,680 | 7,797 | 8,198 | 9,006 | 8,883 | 7,986 |
Selling, General & Admin | 5,721 | 5,811 | 6,407 | 6,404 | 6,374 | 5,772 |
Research & Development | 15.58 | 19.99 | 24.55 | 26.82 | 9.07 | - |
Other Operating Expenses | 158.82 | 161.93 | 116.3 | 93.73 | 180.1 | 139.09 |
Operating Expenses | 5,980 | 6,077 | 6,642 | 6,596 | 6,585 | 5,955 |
Operating Income | 1,700 | 1,720 | 1,556 | 2,411 | 2,298 | 2,031 |
Interest Expense | -194.5 | -194.5 | -258.3 | -248.38 | -261.91 | -288.04 |
Interest & Investment Income | 243.02 | 264.56 | 300.32 | 314.58 | 212.07 | 366.68 |
Currency Exchange Gain (Loss) | 1.37 | 1.37 | -1.85 | 2.95 | -0.44 | 0.41 |
Other Non Operating Income (Expenses) | -61.87 | -43.62 | -28.62 | -27.9 | -1.89 | -4.87 |
EBT Excluding Unusual Items | 1,688 | 1,748 | 1,568 | 2,452 | 2,245 | 2,105 |
Impairment of Goodwill | -253.92 | -253.92 | -887.85 | - | -38.98 | -162.69 |
Gain (Loss) on Sale of Investments | 3.13 | 3.13 | -22.81 | -15.16 | 28.87 | - |
Gain (Loss) on Sale of Assets | 5.7 | 7.96 | 11.87 | 45.31 | 8.31 | 4.25 |
Asset Writedown | -31.4 | -31.84 | -84 | -0.64 | -18.87 | -75.55 |
Legal Settlements | -0.31 | -0.31 | -0.51 | -3.25 | -0.05 | -0.55 |
Other Unusual Items | 36 | 36 | -9.16 | -5.12 | 86.36 | 104.09 |
Pretax Income | 1,448 | 1,509 | 575.47 | 2,473 | 2,311 | 1,975 |
Income Tax Expense | 361.72 | 380.67 | 338.47 | 514.74 | 539.33 | 447.21 |
Earnings From Continuing Operations | 1,086 | 1,128 | 237 | 1,958 | 1,772 | 1,528 |
Minority Interest in Earnings | 9.56 | 7.58 | 405.49 | -359.23 | -285.03 | -191.21 |
Net Income | 1,095 | 1,136 | 642.49 | 1,599 | 1,487 | 1,336 |
Net Income to Common | 1,095 | 1,136 | 642.49 | 1,599 | 1,487 | 1,336 |
Net Income Growth | 88.30% | 76.80% | -59.82% | 7.57% | 11.24% | -4.67% |
Shares Outstanding (Basic) | 556 | 557 | 559 | 557 | 557 | 557 |
Shares Outstanding (Diluted) | 556 | 557 | 559 | 557 | 557 | 557 |
Shares Change (YoY) | -0.54% | -0.38% | 0.26% | 0.12% | - | - |
EPS (Basic) | 1.97 | 2.04 | 1.15 | 2.87 | 2.67 | 2.40 |
EPS (Diluted) | 1.97 | 2.04 | 1.15 | 2.87 | 2.67 | 2.40 |
EPS Growth | 89.24% | 77.39% | -59.93% | 7.49% | 11.25% | -4.59% |
Free Cash Flow | 340.51 | 1,421 | 2,989 | 2,615 | 2,238 | 1,285 |
Free Cash Flow Per Share | 0.61 | 2.55 | 5.35 | 4.69 | 4.02 | 2.31 |
Dividend Per Share | 0.616 | 0.616 | 0.366 | 0.680 | 0.615 | 0.462 |
Dividend Growth | 68.31% | 68.31% | -46.18% | 10.50% | 33.35% | -25.01% |
Gross Margin | 10.53% | 10.62% | 11.02% | 11.93% | 12.09% | 11.68% |
Operating Margin | 2.33% | 2.34% | 2.09% | 3.19% | 3.13% | 2.97% |
Profit Margin | 1.50% | 1.55% | 0.86% | 2.12% | 2.02% | 1.96% |
Free Cash Flow Margin | 0.47% | 1.94% | 4.02% | 3.46% | 3.05% | 1.88% |
EBITDA | 1,579 | 1,932 | 3,102 | 3,836 | 2,542 | 2,239 |
EBITDA Margin | 2.17% | 2.63% | 4.17% | 5.08% | 3.46% | 3.28% |
D&A For EBITDA | -121.32 | 212.01 | 1,545 | 1,426 | 244.32 | 207.45 |
EBIT | 1,700 | 1,720 | 1,556 | 2,411 | 2,298 | 2,031 |
EBIT Margin | 2.33% | 2.34% | 2.09% | 3.19% | 3.13% | 2.97% |
Effective Tax Rate | 24.99% | 25.23% | 58.82% | 20.81% | 23.34% | 22.64% |
Revenue as Reported | 73,416 | 73,416 | 74,378 | 75,477 | - | - |
Advertising Expenses | - | - | - | - | 46.67 | 44.12 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.